MedC Biopharma partners with A2W Pharma to develop therapeutic cannabinoids

Bringing next-generation therapeutic cannabinoids to cancer patients

ONTARIO, June 21, 2022 /PRNewswire/ — MedC Biopharma today announced a partnership with A2W Pharma to Malta in the development of MedC’s new proprietary cannabinoid formulations for the treatment of various cancer-related indications. A2W is a subsidiary of Amino Chemicals of Maltawhich is a subsidiary of ABA Chemicals of Chinaa global pharmaceutical company.

MedC Biopharm is focused on cannabinoid therapeutics. MedC’s methodology rapidly screens synergistic cannabinoid combinations in the treatment of various medical indications. Skin cancers are the main targets of MedC. MedC has so far discovered and developed 2 patented cannabinoid combinations for the treatment of CTCL Sezary, CTCL MF and Actinic Keratosis.

A2W Pharma launched in April 2022 a new cannabinoid production plant in Malta and focuses on bridging the gaps that exist between pharmacology and medicine, providing greater access to the benefits that are found in the cannabis plant.

Pierre Paul FarrugiaDirector of A2W: “A2W draws on the 30 years of experience of its parent company: Amino Chemicals Ltd in API process development, GMP and regulatory compliance, and innovative pathways to target cannabinoids, which makes us the partner of choice for a successful launch of your pharmaceutical preparation”.

The partnership between the organizations was led by Lilac Mandeles, CEO of TechforCann and includes MedC’s exclusivity with A2W and A2W’s commitment to invest around 2 million euro directly into the drug development of MedC’s patented CTCL treatments.

Lilac Mandeles” “Cooperation between the two organizations will accelerate MedC’s clinical and commercial programs, overcome regulatory challenges and bring hope to skin cancer patients worldwide”

Avi DroriMedC CEO: “We are very pleased to collaborate with A2W on our drug development program. A2W’s strategy is a perfect fit with ours, bridging the gap between cannabinoid-based drugs and regulatory requirements with therapeutics synthesized products that provide the safety, consistency and predictability that both patient and physicians rightly expect.”

About MedC Biopharma Corporation

MedC Biopharma Corporation is a clinical-stage biopharmaceutical company focused on the development of therapeutic formulations and drugs based on cannabinoid molecules related to cancer and cancer. Our research and development is carried out by Prof. Hinanit Koltai, who has developed a state-of-the-art drug discovery platform using proprietary high-throughput screening and bioinformatics analysis.

press contact

Avi Drori

SOURCEMedC Biopharma Corporation

Comments are closed.